150 related articles for article (PubMed ID: 7016320)
21. [Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
Noda K; Tanaka K; Ozaki M; Hirabayasi K; Hasegawa K; Nishiya I; Yakushiji M; Izumi R; Tomoda Y; Ogita Y; Sugimori H; Yamabe T; Kudo R; Yajima A; Terashima Y; Fujii S; Suzuoki Y; Okada H; Kono I; Ochiai K; Yamamoto T; Ikeda M; Umesaki N; Saito T; Niitani H
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2061-8. PubMed ID: 9838908
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Delgado G
Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059
[No Abstract] [Full Text] [Related]
23. [A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia].
Moriyama Y; Shibata A; Maekawa I; Yoshida Y; Miura A; Wakui A; Kariyone S; Maekawa T; Miura Y; Abe T
Rinsho Ketsueki; 1985 Nov; 26(11):1774-84. PubMed ID: 3835288
[No Abstract] [Full Text] [Related]
24. Phase II study of etoposide for carcinoma of the prostate.
Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
Cancer Treat Rep; 1986 Jun; 70(6):771-2. PubMed ID: 3524825
[TBL] [Abstract][Full Text] [Related]
25. [New antineoplastic drugs of the podophyllotoxin derivative group].
Robak T; Płuzańska A
Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
[No Abstract] [Full Text] [Related]
26. Phase II study of etoposide in the treatment of esophageal carcinoma.
Coonley CJ; Bains M; Heelan R; Dukeman M; Kelsen DP
Cancer Treat Rep; 1983 Apr; 67(4):397-8. PubMed ID: 6850656
[No Abstract] [Full Text] [Related]
27. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
Panduro J; Hansen M; Hansen HH
Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
[No Abstract] [Full Text] [Related]
28. Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.
Slavik M; Muss H; Blessing JA; Delgado G
Cancer Treat Rep; 1982 Sep; 66(9):1775-7. PubMed ID: 6288239
[No Abstract] [Full Text] [Related]
29. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.
Hahn RG; Bauer M; Wolter J; Creech R; Bennett JM; Wampler G
Cancer Treat Rep; 1979 Mar; 63(3):513-5. PubMed ID: 371804
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of VP-16-213 in non-small-cell lung cancer.
Itri LM; Gralla RJ; Chapman RA; Kelsen DP; Casper ES; Golbey RB
Am J Clin Oncol; 1982 Feb; 5(1):45-7. PubMed ID: 7081137
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
Lokich J; Corkery J
Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
[TBL] [Abstract][Full Text] [Related]
32. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study.
Conroy JF; Blessing JA; Kessinger A; Homesley HD
Cancer Treat Rep; 1984 Feb; 68(2):439-40. PubMed ID: 6697335
[No Abstract] [Full Text] [Related]
34. [Phase II study of etoposide in malignant lymphoma].
Onoshi T; Hayashi K; Ueoka H; Nishihara R; Toyota K
Gan To Kagaku Ryoho; 1984 Apr; 11(4):952-3. PubMed ID: 6721509
[No Abstract] [Full Text] [Related]
35. VP-16-213. A phase II trial using a weekly schedule.
Karp G; Antman K; Canellos G
Cancer Clin Trials; 1981; 4(4):465-7. PubMed ID: 7318129
[TBL] [Abstract][Full Text] [Related]
36. PHASE I clinical trial of an oral solution of VP-16-213.
Nissen NI; Dombernowsky P; Hansen HH; Larsen V
Cancer Treat Rep; 1976 Jul; 60(7):943-5. PubMed ID: 1009527
[No Abstract] [Full Text] [Related]
37. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
[TBL] [Abstract][Full Text] [Related]
38. Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.
Ahmann DL; Bisel HF; Eagan RT; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
Cancer Treat Rep; 1976 May; 60(5):633-5. PubMed ID: 1036468
[No Abstract] [Full Text] [Related]
39. [1st experiences in the treatment of ovarian tumors with Peptichemio].
Natale N; Mangioni C; Remotti G
Minerva Med; 1974 May; 65(33):1805-10. PubMed ID: 4367233
[No Abstract] [Full Text] [Related]
40. Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.
Felix W; Senn HJ
Cancer Chemother Rep; 1975; 59(4):737-42. PubMed ID: 1100224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
